Calcineurin inhibitor and non-steroidal anti-inflammatory drug to reduce risk of post-imaging pancreatitis
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorSohail HUSAIN
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for targeted administration to the pancreas of a calcineurin inhibitor and a non-steroidal anti-inflammatory drug (“NSAID”) to reduce the risk and/or limit the extent of post-imaging pancreatitis associated with procedures that employ a radiocontrast medium, particularly procedures that selectively image the pancreas, gallbladder and/or biliary tree.
Claims47
A radiocontrast medium comprising effective amounts of:
- (i) a radiocontrast agent;
- (ii) a calcineurin inhibitor;
- and (iii) a NSAID.
A kit comprising a radiocontrast medium comprising:
- (i) a radiocontrast agent;
- (ii) a calcineurin inhibitor;
- and (iii) a NSAID.
A pharmaceutical composition comprising effective amounts of (i) a calcineurin inhibitor and (ii) a NSAID in a pharmaceutically suitable excipient.
A method for reducing the risk or extent of post-imaging pancreatitis in a subject in need of such treatment, comprising administering, to the subject, a radiocontrast medium comprising effective amounts of a radiocontrast agent, a calcineurin inhibitor, and a NSAID.
A method for reducing the risk or extent of post-imaging pancreatitis in a subject in need of such treatment, comprising administering, to the subject, a pharmaceutical composition that does not contain radiocontrast medium but comprises effective amounts of a calcineurin inhibitor and a NSAID.
A method for reducing the risk or extent of post-imaging pancreatitis in a subject in need of such treatment, comprising introducing, into the subject, a pancreatic stent having a coating on at least a portion of one surface comprising a calcineurin inhibitor and a NSAID.
A radiocontrast medium comprising effective amounts of a radiocontrast agent, a calcineurin inhibitor, and a NSAID, for use in reducing the risk or extent of post-imaging pancreatitis in a subject.
A pharmaceutical composition that does not contain radiocontrast medium but comprises an effective amount of a calcineurin inhibitor and a NSAID, for use in reducing the risk or extent of post-imaging pancreatitis in a subject.
A stent for placement in a pancreas having a coating on at least a portion of one surface, said coating comprising effective amount(s) of a calcineurin inhibitor and/or NSAID.
Dependencies are inferred from the claim text.